Accueil>>Natural Products>>Ganoderic acid C2

Ganoderic acid C2

Catalog No.GC36117

L'acide ganodérique C2 est un triterpénoÏde bioactif du Ganoderma lucidum. L'acide ganodérique C2 possède une bioactivité anti-tumorale potentielle, des effets antihistaminiques, anti-Âge et cytotoxiques. L'acide ganodérique C2 présente une activité inhibitrice élevée contre l'aldose réductase de la lentille de rat (RLAR) avec une IC50 de 3,8 μM.

Products are for research use only. Not for human use. We do not sell to patients.

Ganoderic acid C2 Chemical Structure

Cas No.: 103773-62-2

Taille Prix Stock Qté
1mg Please Inquire Please Inquire
5mg Please Inquire Please Inquire

Tel:(909) 407-4943 Email: sales@glpbio.com

Avis des clients

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Ganoderic acid C2 is a bioactive triterpenoid in Ganoderma lucidum. Ganoderic acid C2 possesses the potential anti-tumor bioactivity, antihistamine, anti-aging and cytotoxic effects. Ganoderic acid C2 exhibits high inhibitory activity against the rat lens aldose reductase (RLAR) with an IC50 of 3.8 µM[1][2]. IC50: 3.8 µM (RLAR)[2]

[1]. Guo XY, et al. l characterization of minor metabolites and pharmacokinetics of ganoderic acid C2 in rat plasma by HPLC coupled with electrospray ionization tandem mass spectrometry. J Pharm Biomed Anal. 2013 Mar 5;75:64-73. [2]. Fatmawati S, et al. Inhibition of aldose reductase in vitro by constituents of Ganoderma lucidum. Planta Med. 2010 Oct;76(15):1691-3.

Avis

Review for Ganoderic acid C2

Average Rating: 5 ★★★★★ (Based on Reviews and 34 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Ganoderic acid C2

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.